CVS Health CVS and The Cigna Group CI stand as two dominant forces in the U.S. diversified healthcare sector, commanding market capitalizations of approximately $77 billion and $84 billion, respectively. Both companies have strategically integrated pharmacy benefit management, insurance coverage and care delivery into comprehensive, consumer-focused platforms designed to address the complexities of modern healthcare.

As the industry faces intensifying policy challenges, rapid growth in GLP-1 therapies and a pressing need for digital transformation, a critical question emerges for investors i.e. which of these healthcare leaders is better positioned to sustain long-term growth and deliver value in an increasingly dynamic market environment? Let's find out.

CVS Stock is an Outperformer Compared to CI & S&P 500

Year to date, CVS Health shares have surged 39.7%, significantly outpacing both Cigna’s 14.7% gain and the S&P 500’s 1.3% decline. CVS’ strong stock performance reflects growing investor confidence in the company’s turnaround strategy and execution under its revamped leadership team. Key drivers include the successful stabilization of its Aetna segment, better-than-expected first-quarter earnings, and a raised full-year EPS guidance. This sharp rebound has helped CVS Health become one of the top-performing stocks in the S&P 500 in 2025, signaling renewed momentum in its long-term growth narrative.

Image Source: Silkcharts

Meanwhile, Cigna stock’s gain reflects the strong performance of the Evernorth Health Services segment, driven by specialty pharmacy, biosimilars and pharmacy benefit services. The divestiture of its Medicare businesses to HCSC has sharpened its focus on higher-margin commercial insurance and health services. Cigna's leadership in GLP-1 affordability, through initiatives like EncircleRx and the upcoming EnGuide platform, further enhances its positioning.

While trailing CVS Health in near-term gains, Cigna’s disciplined capital strategy and 10-14% long-term EPS growth target continue to appeal to long-term investors.

Image Source: Zacks Investment Research

Diverging Paths, Long-Term Prospects of CVS & CI

CVS Health and Cigna are executing distinct strategies for long-term growth, shaped by structural strengths and market positioning.

CVS Health is leveraging its integrated ecosystem with 1.7 billion scripts filled each year and 9,000 community health locations to drive care coordination and cost-efficiency. Its strong first-quarter 2025 results (EPS grew 71.8% year over year and exceeded the Zacks Consensus Estimate by 34.7%, while adjusted operating income surged 54.8%) and raised full-year guidance signal resilience after a tough 2024. Its pivot to core segments like Medicare Advantage and divestiture of ACA exchange plans are aimed at streamlining profitability. However, regulatory friction and GLP-1 utilization trends pose near-term risks.